Login / Signup

89 Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.

Daan G J LindersM M DekenMartijn A van DamMartin N J M WasserE M C VoormolenJudith R KroepG A M S van DongenD VugtsH M OosterkampM E StraverC J H van de VeldeD CohenPetra Dibbets-SchneiderFloris H P van VeldenL M Pereira Arias-BoudaA L VahrmeijerG J LiefersLioe-Fee De Geus-OeiDenise E Hilling
Published in: Cancers (2023)
Zr-trastuzumab PET/CT has potential for a more accurate response evaluation of the primary tumor after NAT in HER2-positive breast cancer.
Keyphrases